Canaccord keeps Buy for CVRx stock as CVRx appoints John Landry CFO

Published on 10/06/2026 at 09:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVRx named John Landry CFO on September 21, 2026, starting October 12. Canaccord kept a USD 5.00 target for CVRx stock on September 22, 2026.

CVRX, US1266381052, Illustration mit AI erstellt.

Canaccord Genuity kept its Buy rating and USD 5.00 price target for CVRx stock on September 22, 2026, while CVRx had appointed John Landry as chief financial officer on September 21. The leadership change gives the medical-device company a near-term execution milestone as it works through sales and reimbursement pressure.

New CFO starts October 12

According to the SEC filing dated September 21, 2026, Landry will join CVRx on October 12, 2026 and succeed Jared Oasheim after the company files its Form 10-Q for the quarter ending September 30, 2026. His annual base salary is USD 500,000, with a target cash incentive equal to 50 percent of base salary.

The filing also says the initial equity awards will represent 0.80 percent of total common shares outstanding when Landry begins. Landry previously served as chief financial officer of Nyxoah and Vapotherm, giving CVRx an executive with medical-technology finance experience.

Revenue growth meets execution risk

CVRx reported USD 15.7 million of revenue in the second quarter of 2026, up 16 percent from the prior-year quarter, according to Investing.com. The result exceeded the USD 15.55 million consensus estimate, but earnings per share came in at a loss of USD 0.53 versus a consensus loss of USD 0.52.

The same report said CVRx cut its full-year 2026 revenue outlook and cited sales execution challenges and inconsistent reimbursement from its largest payer. The third-quarter 2026 revenue outlook stood at USD 13.5 million to USD 14.5 million, a range below the second-quarter result and a concrete test for the new finance leadership.

Analyst target remains above results

Canaccord kept its USD 5.00 target and Buy rating after the CFO appointment, while Investing.com reported that Piper Sandler had cut its target from USD 12.00 to USD 4.00 and moved its rating from Overweight to Neutral. Cantor Fitzgerald reduced its target from USD 13.00 to USD 5.00 while retaining Overweight.

That split shows the central issue for CVRx: revenue growth remains measurable, but sales productivity and payer access determine whether growth can translate into a narrower loss. CVRx develops Barostim, a neuromodulation system for selected heart-failure patients, and operates in the healthcare equipment industry.

Market value and Nasdaq listing

CVRx had a market capitalization of USD 41.4 million as of October 5, 2026. Its common stock is listed on the Nasdaq Global Select Market under ticker CVRX, according to the September 21, 2026 SEC filing.